Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.39 |
| ▸ | NPC1 | O15118 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12964193 | 0.84 | RAB9A (0.41) | RAB9ANPC1SMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL13127186 | 0.78 | NPC1 (0.37) | RAB9ANPC1SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL10271271 | 0.78 | — | — | |
| SCHEMBL7982657 | 0.76 | — | — | |
| SCHEMBL9829014 | 0.76 | — | — | |
| SCHEMBL15725262 | 0.70 | ALDH1A1 (0.57) | RAB9ANPC1SMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL15709961 | 0.68 | GAA (0.45) | RAB9ANPC1SMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL10864727 | 0.67 | PDCD1 (0.36) | RAB9ANPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL2212043 | 0.66 | — | — | |
| SCHEMBL6181092 | 0.66 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178491-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-20090257978-A1 | Antiviral coumpounds | GILEAD SCIENCES, INC. (US) | 2009-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090257978-A1 | Antiviral coumpounds | MAVS, ZC3HAV1, EIF2AK2 | RAB9A 3277/4885NPC1 216/4885SMN1; SMN2 3291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.